. 2023 Jan 3;5(3):100668. doi: 10.1016/j.jhepr.2022.100668

Table 2.

Risk factors for steatosis and NASH recurrence.

	Steatosis recurrence			NASH recurrence
	Univariate p value	Multivariate analysis		Univariate p value	Multivariate analysis
	Univariate p value	OR (95% CI)	p value	Univariate p value	OR (95% CI)	p value
Clinical characteristics before LT
Sex (M/F)	0.269			0.634
Age at LT time	0.012			0.004
Age ≥50 years	0.145			0.285
Age ≥55 years	0.276			0.098	1.470 (0.542-3.988)^∗	0.449^∗
Age ≥60 years	0.452			0.040	1.673 (0.716-3.193)^∗	0.235^∗
Age ≥62 years	0.307			0.002	0.397 (0.145-1.089)^∗	0.073^∗
Age ≥65 years	0.383			0.035	0.237 (0.058-0.964)^∗	0.044^∗
BMI at LT time	0.149			0.020
≥20 kg/m²	0.809			0.564
≥25 kg/m²	0.817			0.215
≥30 kg/m²	0.056			0.0001	5.086 (1.000-28.857)∗∗	0.050∗∗
≥31 kg/m²	0.002	2.727 (1.048-7.098)^∗	0.040	0.0001	11.017 (2.073-58.538)∗∗	0.005∗∗
≥32 kg/m²	0.003	1.766 (0.726-4.297)^∗	0.210	0.001	5.715 (1.116-29.270)∗∗	0.036∗∗
≥35 kg/m²	0.201			0.293
Pre-LT HCC	0.538			0.856
Pre-LT diabetes	0.108			0.892
Pre-LT HbA1c ≥7%	0.602			0.621
Pre-LT insulin therapy	0.115			0.272
Pre-LT arterial hypertension	0.411			0.439
Pre-LT metabolic syndrome	0.043	1.029 (0.501-2.115)	0.937	0.046	0.775 (0.286-2.098)	0.616
Active smoking before LT	0.810			0.836

Donor characteristics
Age of the donor (years)	0.497			0.120
Age ≥60 years	0.091	1.466 (0.832-2.584)	0.185	0.575
Age ≥70 years	0.821			0.651
Donor age + recipient age (years)	0.185
≥120 years	0.260			0.926
≥135 years	0.829			0.984
Donor BMI (kg/m²)	0.378			0.333
Graft steatosis (≥5%)	0.162			0.191
Grade ≥2 steatosis	0.121			0.137

Metabolic events after LT
BMI at 1 year after LT	0.008			0.054
≥30 kg/m²	0.0001	0.976 (0.426-2.240)^∗	0.955	0.0001	0.277 (0.286-1.216)∗∗∗	0.089∗∗∗
≥32 kg/m²	0.002	1.197 (0.654-2.191)^∗	0.560	0.008	0.521 (0.193-1.409)∗∗∗	0.199∗∗∗
≥35 kg/m²	0.023	1.313 (0.623-2.766)^∗	0.474	0.227
Weight difference 1-year post-LT (kg)	0.148			0.805
Diabetes post-LT	0.974			0.635
Arterial hypertension post-LT	0.452			0.587
TG ≥1.7 mmol/L post-LT	0.248			0.527
LDL-c ≥3.70 mmol/L post-LT	0.474			0.566
HDL-c <1.15 mmol/L	0.402			0.050	3.463 (1.301-9.220)	0.013
HbA1c ≥6.5%	0.205			0.150
HbA1c ≥7%	0.333			0.330
HbA1c ≥8%	0.052	1.676 (0.939-2.990)	0.080	0.194
Metabolic syndrome post-LT	0.363			0.655

Immunosuppressive regimen
Tacrolimus	0.163			0.098
MMF	0.101			0.629
CYA	0.375			0.934
mTOR-i	0.930			0.675
CST	0.071	0.337 (0.074-1.547)	0.162	0.307
AZA	0.377			0.673

Specifics therapies after LT
Statin therapy	0.985			0.519
Fibrate therapy	0.329			0.377
Insulin therap	0.157			0.573
Dyslipidemia or lipid drugs	0.047	1.831 (0.883-3.795)	0.104	0.910

Complications after LT
CV events	0.050	0.764 (0.444-1.313)	0.330	0.420
OSAS	0.056	1.130 (0.605-2.109)	0.701	0.363
Acute rejection	0.627			0.587

Disease recurrence on the graft at 1 year
Grade ≥1 steatosis				0.002	10.521 (2.127-52.046)∗∗∗∗	0.004∗∗∗∗
Grade ≥2 steatosis				0.0001	10.196 (3.553-29.257)∗∗∗∗	0.001∗∗∗∗
Grade 3 steatosis				0.0001	2.729 (0.845-8.815)∗∗∗∗	0.093∗∗∗∗

Each variable was tested in univariate analysis. All variables with a p value <0.010 were retained for the multivariate model.

Univariate analysis was performed using log-rank analysis or Mann-Whitney analysis (for quantitative variables). All significant variables in the univariate analysis with a level set at p <0.1 were incorporated into multivariate models analyzed with binary logistic Cox regression. Values in bold are considered significant (<0.005).

AZA, azathioprine; CNI, calcineurin inhibitor; CST, corticosteroids; CYA, cyclosporine A; CV, cardiovascular; HbA1c, glycated hemoglobin; HCC, hepatocellular carcinoma; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; LT, liver transplantation; MMF, mycophenolate mofetil; mTOR-i, mTOR inhibitor; TG, triglyceride.

^∗

Because these variables are not independent, different multivariate analysis models were tested.